MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
MAGE family member A3
MAGEA3
adoptive T cell therapy
cancer testis antigen
immunotherapy
malignant fibrous histiocytoma
myxofibrosarcoma
pleomorphic sarcoma
sarcoma
tissue microarray
undifferentiated pleomorphic sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 May 2019
15 May 2019
Historique:
received:
04
04
2019
revised:
08
05
2019
accepted:
10
05
2019
entrez:
18
5
2019
pubmed:
18
5
2019
medline:
18
5
2019
Statut:
epublish
Résumé
Melanoma-associated antigen 3 (MAGE-A3) expression is generally restricted to the placenta and germline cells of the testis, but it may also be expressed in sarcoma and other cancers and is associated with poor prognosis. Immunotherapy approaches targeting MAGE-A3 in other cancers have shown mixed results in the clinic, however, use of cancer testis antigens such as MAGE-A3 may have therapeutic value in the treatment of soft tissue sarcomas. Based on the recent success of anti-programmed death-1 (PD-1) therapy in undifferentiated pleomorphic sarcoma, we hypothesize that MAGE-A3-based immunotherapies may also provide benefits in this sarcoma type. We analyzed MAGE-A3 expression of sarcoma subtypes available in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia and show that undifferentiated pleomorphic sarcoma/myxofibrosarcoma (UPS/MFS) expresses this potential target gene. We have identified high protein expression by tissue microarray of 106 UPS cores. We also found that high MAGE-A3 mRNA and protein expression is associated with worse overall survival in UPS/MFS. Furthermore, our results show no human leukocyte antigen (HLA) expression loss and relatively high lymphocyte infiltration by lymphocyte specific protein tyrosine kinase (LCK) marker expression. Based on these results, we propose targeting MAGE-A3 in UPS/MFS by immunotherapy techniques.
Identifiants
pubmed: 31096717
pii: cancers11050677
doi: 10.3390/cancers11050677
pmc: PMC6562561
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Cancer. 2000 Feb 15;85(4):460-5
pubmed: 10699915
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6
pubmed: 12601173
Eur J Cardiothorac Surg. 2004 Jan;25(1):131-4
pubmed: 14690745
Mol Cell. 2010 Sep 24;39(6):963-74
pubmed: 20864041
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
PLoS One. 2011;6(8):e20294
pubmed: 21826194
Hematology. 2011 Nov;16(6):368-72
pubmed: 22183072
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Theory Biosci. 2012 Dec;131(4):281-5
pubmed: 22872506
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Hum Vaccin Immunother. 2014;10(11):3117-24
pubmed: 25625925
J Cancer Res Ther. 2015 Nov;11 Suppl:C271-4
pubmed: 26612451
Ann Surg Oncol. 2016 Jul;23(7):2220-8
pubmed: 26847678
Cell Oncol (Dordr). 2016 Apr;39(2):175-86
pubmed: 26868260
Lancet Oncol. 2016 Jun;17(6):822-835
pubmed: 27132212
Dis Markers. 2016;2016:1987505
pubmed: 27635108
J Invest Dermatol. 2017 Mar;137(3):775-778
pubmed: 27826009
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Curr Oncol Rep. 2017 Oct 13;19(12):78
pubmed: 29030741
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Int J Mol Sci. 2017 Dec 08;18(12):null
pubmed: 29292724
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Ther Adv Med Oncol. 2017 Dec;9(12):755-767
pubmed: 29449896
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
Lancet Oncol. 2018 Jul;19(7):916-929
pubmed: 29908991
Trends Cancer. 2018 Jul;4(7):463-465
pubmed: 29937043
J Exp Med. 1994 Mar 1;179(3):921-30
pubmed: 8113684